ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adul...( KENILWORTH N.J. July 9 /- Schering-Pl...),Health

KENILWORTH, N.J., July 9 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ASMANEX TWISTHALER (mometasone furoate dry powder inhaler) for the treatment of bronchial asthma in adults.(1)

"We are pleased to announce the approval of the ASMANEX TWISTHALER in Japan," said Thomas P. Koestler, Ph.D., executive vice president and president, Schering-Plough Research Institute. "ASMANEX was discovered and developed by Schering-Plough Research Institute and offers physicians and patients in Japan an effective inhaled corticosteroid to treat bronchial asthma in an innovative dry powder inhaler device," Koestler added. "Schering-Plough K.K. has received eight total new chemical entity approvals in Japan during the past two years, underscoring Schering-Plough's commitment to improving health and well being for patients in Japan."

Important Information about ASMANEX in the United States

Clinical studies with ASMANEX have shown improvement in lung function, decreased use of rescue medication, and improvement in daytime symptoms in patients 12 and older.

ASMANEX is approved for the maintenance treatment of asthma in patients 4 years of age and older. ASMANEX will not relieve sudden asthma symptoms and is not for children less than 4 years of age.

In the U.S., it is available in two dose strengths, 110 mcg for children between 4 and 11 years old, and 220 mcg for patients 12 and older.

Important Safety Information

ASMANEX is not a rescue inhaler and should not be used to treat sudden asthma symptoms. Use a rescue inhaler to relieve sudden asthma symptoms.

ASMANEX should not be used to treat acute asthma episodes
'/>"/>